Efficiency in oncology: the role of the pharmacist
The hospital pharmacist plays a key role in safe handling of products and devices, robotics, the use of biosimilars, dose-banding and cost-control of cytostatic therapy. Safety and efficiency are key drivers as discussed by the HPE Advisory Board (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 2, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
Management and prevention of vesicant extravasations
Extravasation is a therapeutic emergency that does not support improvisation and it is paramount to be aware of the described treatments and principles for prevention and management (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 2, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
Electronic prescribing – key to medication safety
More than 800 pharmacists attended the German Hospital Pharmacists’ Association congress in Hamburg in May 2014. Key themes included electronic prescribing, unit dose dispensing, robotic preparation and decision-support systems (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 2, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
DIFICLIR proven to be clinically and cost-effective compared to standard of care in patients with CDI
New analysis from a unique real-world study demonstrates that first-line use of fidaxomicin, is clinically effective in reducing recurrence rates and lowering mortality, and provides cost savings for the treatment of potentially fatal Clostridium difficile infection (CDI). (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 26, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Cost effectiveness cdi fidaxomicin hospital hygiene protocols Latest News Source Type: news
New data shows improved overall survival for prostate cancer patients treated with FIRMAGON®
New data published in the December issue of the European Journal of Urology indicates improvement in overall survival (OS) and prostate specific antigen progression free survival (PSA PFS) for degarelix (FIRMAGON®), a gonadotropin releasing hormone (GnRH) antagonist, compared to commonly prescribed luteinising hormone-releasing hormone (LHRH) agonists. (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 26, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Patient care firmagon gonadotropin releasing hormone antagonist Latest News luteinising hormone-releasing hormone agonists prostate cancer prostate specific antigen progression fre Source Type: news
Genmab announces Phase II study of Daratumumab in smouldering multiple myeloma
Genmab A/S announced that its collaboration partner, Janssen Biotech, Inc. plans to start a Phase II study of daratumumab in smouldering multiple myeloma. The study (SMM2001) will evaluate three different dose schedules of daratumumab for the treatment of smouldering multiple myeloma. The study is expected to start enrolling patients in 2015. (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 25, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Haematology Oncology Patient care CD38 monoclonal antibody daratumumab immunomodulatory agent Latest News smouldering multiple myeloma Source Type: news
Victoza® receives positive CHMP opinion
The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion for the use of Victoza® (liraglutide) in adults with type 2 diabetes and moderate renal impairment. Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Victoza®, the once-daily human glucagon-like peptide-1 (GLP-1) analogue, to adults with type 2 diabetes and moderate renal impairment without dose adjustments. (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 24, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Nephrology Patient care chmp positive opinion diabetes type 2 glp-1 Latest News liraglutide renal impairment Source Type: news
Celgene receives positive CHMP opinion for OTEZLA® (apremilast)
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for OTEZLA® (apremilast), the company’s oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications. (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 21, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Rheumatology apremilast chmp DMARDs Latest News OTEZLA PASI-75 PDE4 inhibitor psoriasis Source Type: news
New data at ACR meeting show efficacy of Simponi® in active non-radiographic Axial Spondyloarthritis
MSD announced findings from the GO-AHEAD study (1) showing that patients with active non-radiographic axial spondyloarthritis (nr-AxSpA) treated with injections of Simponi® (golimumab) 50 mg every 4 weeks for 16 weeks had significantly greater improvements in disease activity and inflammation on magnetic resonance imaging (MRI) than patients treated with placebo. (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 19, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Rheumatology Patient care GO-AHEAD study golimumab Latest News non-radiographic axial spondyloarthritis Simponi Source Type: news
New guidelines on palliative care in Scotland published
Supported by Healthcare Improvement Scotland and the Scottish Partnership for Palliative Care, the updated guidelines reflect expert opinion about good practice in the management of adult patients at the end of life. The guidelines provide practical, evidence-based or best practice guidance on a range of common clinical issues including pain management, symptom control, palliative care emergencies, end of life care and use of medicines. (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 19, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Industry News Palliative care Patient care best practice guidance Latest News quality of life Source Type: news
Medi-Dose/EPS announces new metric-only oral syringes meeting ISMP recommendations
EPS has released 3 new styles of oral syringes. All were designed with METRIC-ONLY markings, meeting the latest ISMP recommendations. Eight sizes, ranging from 0.5ml to 60ml, are immediately available. Syringes are stocked in either clear – with orange or blue graduations – or in light-protecting, ultraviolet inhibiting amber with white graduations. (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 18, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Cost effectiveness Industry News Guidelines IV Fluid therapy /nutrition Patient care Latest News Medi-Dose/EPS medication safety oral syringes Source Type: news
Patients suffering from medicines shortages in all European countries
A new report on medicines shortages experienced in European healthcare systems reveals that over 86% of hospital pharmacists are experiencing difficulties in sourcing medicines with 66% reporting this as a daily or weekly problem. The top affected areas are medicines to fight infection, cancer drugs and anaesthetics. (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 17, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Drug shortages Industry News Patient safety Pharmacoeconomics Conference reports Patient care eahp Latest News medicines shortages Source Type: news
Ablynx to present data on its anti-IL-6R Nanobody, developed in partnership with Abbvie
Ablynx announced that it will present two posters on its novel anti-IL-6R Nanobody®, ALX-0061, at the 2014 American College of Rheumatology (ACR/ARHP) Annual Meeting, which is taking place from 14 to 19 November 2014 in Boston, MA, USA. (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 14, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Rheumatology ACR 2014 ALX-0061 IL-6R Nanobody Latest News rheumatoid arthritis Source Type: news
Scottish Medicines Consortium decision on Afinitor® (Everolimus)
The Scottish Medicines Consortium (SMC) has issued a positive recommendation for everolimus, which has been accepted for use in NHS Scotland, as a treatment option for advanced kidney cancer patients who have failed on or after one previous vascular endothelial growth factor (VEGF)-targeted therapy. (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 11, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Oncology advanced kidney cancer everolimus Latest News scottish medicines consortium VEGF-targeted therapy Source Type: news
